79,463 Shares in Boston Scientific Corporation $BSX Purchased by Exane Asset Management

Exane Asset Management purchased a new position in Boston Scientific Corporation (NYSE:BSX) during the third quarter, HoldingsChannel reports. The institutional investor purchased 79,463 shares of the medical equipment provider’s stock, valued at approximately $7,758,000. Boston Scientific makes up about 2.8% of Exane Asset Management’s holdings, making the stock its 9th largest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of BSX. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after acquiring an additional 2,545,381 shares during the last quarter. State Street Corp raised its stake in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after purchasing an additional 622,602 shares during the last quarter. Norges Bank purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at $2,089,937,000. Finally, Invesco Ltd. increased its holdings in shares of Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after buying an additional 226,578 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 80,204 shares of company stock valued at $7,998,563 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $93.63 on Wednesday. The firm has a fifty day simple moving average of $95.42 and a 200-day simple moving average of $99.69. The company has a market capitalization of $138.81 billion, a PE ratio of 50.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Friday, November 21st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, January 21st. Evercore ISI set a $112.00 target price on Boston Scientific in a report on Monday, January 5th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Royal Bank Of Canada increased their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $123.89.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.